Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 16/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 15/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 15/20 | 1.00 |
| ▸ | GCGR | P47871 | 14/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.79 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.79 |
| ▸ | FRK | P42685 | 4/20 | 0.79 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.79 |
| ▸ | GSK3B | P49841 | 4/20 | 0.79 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.79 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.79 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.79 |
| ▸ | ALOX5 | P09917 | 12/20 | 0.74 |
| ▸ | PRKACA | P17612 | 3/20 | 0.70 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7231228 | 0.90 | MAPK11 (0.81) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL15075603 | 0.89 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL19868925 | 0.89 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6466765 | 0.88 | MAPK13 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6465608 | 0.88 | MAPK13 (0.81) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL19868922 | 0.87 | MAPK14 (0.76) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL6469126 | 0.85 | MAPK13 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL2649616 | 0.85 | MAPK13 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL2650684 | 0.85 | MAPK11 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR | |
| SCHEMBL2648969 | 0.85 | MAPK13 (1.00) | MAPK11MAPK14MAPK13MAPK12GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | claimed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | claimed |
| EP-0959885-A4 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO INC (US) | 2002-07-17 | — | — | EP | claimed |
| EP-0959885-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | Merck & Co., Inc. (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998022108-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | claimed |
| US-20240000821-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | UNIV JOHNS HOPKINS (US) | 2024-01-04 | — | — | US | disclosed |
| US-20200078387-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY | 2020-03-12 | — | — | US | disclosed |
| WO-2018112342-A1 | CHEMICAL INHIBITORS AGAINST KINASES TO BLOCK TELOMERE ELONGATION IN CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180044316-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-02-15 | — | — | US | disclosed |
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | AXXIMA PHARMACEUTICAL AG. (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1532118-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004005264-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2004-01-15 | — | — | WO | disclosed |
| EP-0959885-A4 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO INC (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0959885-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | Merck & Co., Inc. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998022108-A1 | TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE | MERCK & CO., INC. (US) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203155-A1 | Imidazole compounds and human cellular proteins casein kinase I alpha, delta and epsilon as targets for medical intervention against Hepatitis C Virus infections | CSNK1G1, CSNK1E, CSNK1D | MAPK11 1215/4885MAPK14 662/4885MAPK13 456/4885 |
| US-20180044316-A1 | POTENTIATORS OF BETA-LACTAM ANTIBIOTICS | CREB1, PPP6R1, PPP1R10 | MAPK11 903/4885MAPK14 440/4885MAPK13 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.